FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
371 letters match. Newest first.
-
DrugsCitra100mg
FDA warns Citra100mg it sells unapproved, misbranded tramadol opioids without prescriptions to U.S. consumers online.
High risk -
DrugsZeuss LLC dba Zeuss
FDA warned telehealth seller Zeuss that its website misbrands compounded tirzepatide by implying Zeuss makes it and that it is FDA-approved.
Medium -
DrugsLean Rx, Inc. dba SkinnyRx
SkinnyRx's website misbranded compounded semaglutide and tirzepatide by wrongly suggesting it makes the drugs and that they are FDA-approved.
Low -
DrugsKare Solutions, LLC dba Zappy
FDA warned Zappy that its website falsely suggested it compounds semaglutide, tirzepatide, and liraglutide and made misleading approval-like claims.
Low -
DrugsRefills Health, LLC dba Refills Health
FDA told telehealth seller Refills Health its website misbrands compounded semaglutide by implying FDA approval and naming itself as maker.
Medium -
DrugsWeightless Medical LLC dba WeightCare
FDA warned telehealth seller WeightCare that its website falsely presents it as the compounder of semaglutide and tirzepatide drugs.
Low -
DrugsViv Health, Inc. dba VIV RX
FDA warned telehealth company VIV RX that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.
Medium -
DrugsGood Girl LLC dba GoodGirlRX
FDA warns telehealth seller GoodGirlRX that its website misbrands compounded semaglutide and tirzepatide, claiming FDA approval and implying it is the compounder.
Medium -
DrugsIvim Services LLC dba Ivim
FDA says Ivim's telehealth website mislabels compounded semaglutide and tirzepatide as Ivim-made when it is not the compounder.
Low -
DrugsJoin Josie
FDA says Join Josie's website misbranded compounded semaglutide and tirzepatide by falsely implying FDA approval and naming Join Josie as compounder.
Low -
DrugsKin Meds
FDA warned Kin Meds over false claims for compounded semaglutide and tirzepatide, including implying it is the compounder and that products are approved.
Low -
DrugsLevity Inc. dba Levity
FDA warned Levity over misleading website claims for compounded semaglutide and liraglutide, including implying Levity made the drugs and that they were FDA-approved.
Low -
DrugsMaxLife Technologies Inc. dba Maxlife
FDA told telehealth seller Maxlife its website falsely implied Maxlife compounds semaglutide and tirzepatide and that the drugs are FDA-approved.
Medium -
DrugsBetter Health Labs, Inc. dba Measured
FDA warned telehealth seller Measured its website misbranded compounded semaglutide and tirzepatide by implying it made them and that they were FDA-approved.
Medium -
DrugsMEDVi, LLC dba MEDVi
FDA says telehealth seller MEDVi misbranded compounded semaglutide and tirzepatide by implying MEDVi makes them and that they are FDA-approved.
Medium -
DrugsNewman Clinic, PLLC dba Newman Clinic
FDA told Newman Clinic its website misbranded compounded semaglutide and tirzepatide with false and misleading claims.
Medium -
DrugsNewSelf Limited dba NewSelf
FDA warns NewSelf over misleading website claims for compounded semaglutide and tirzepatide, including false compounder and FDA-approval implications.
Low -
Drugs24HrDoc, Inc. dba 24HrDoc
FDA says 24HrDoc's website misbrands compounded semaglutide and tirzepatide with false claims that it compounds them and that they match Ozempic, Wegovy, Mounjaro, Zepbound.
Medium -
DrugsAlan Health Technologies Inc. dba Alan
FDA warns Alan Health Technologies over website falsely labeling compounded semaglutide and tirzepatide as Alan-made.
Low -
DrugsDripgym Mobile Parent, LLC dba Amp Health
FDA warned Amp Health that its website misbranded compounded semaglutide and tirzepatide with false maker and approval-implying claims.
Low -
DrugsBelle Health LLC dba Belle
FDA warned Belle Health that its website falsely suggests Belle compounds semaglutide and tirzepatide, making the drugs misbranded.
Low -
DrugsBliv Wellness LLC dba Bliv
FDA warns Bliv Wellness that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.
Medium -
DrugsBluefitMD
FDA warned BluefitMD that its website falsely labels compounded semaglutide and tirzepatide as its own and as FDA-approved.
Low -
DrugsDeluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics
FDA warned Deluxe IV and Aesthetics over misleading website claims for compounded semaglutide and tirzepatide, including implying FDA approval.
Low -
DrugsAspen Aesthetics dba Fifty 410
FDA warns Fifty 410 over misleading website claims for compounded semaglutide and tirzepatide, including implied compounding and 'clinically proven' claims.
Low -
DrugsFitRX, LLC dba FitRx
FitRx's website misbranded compounded semaglutide and tirzepatide with false and misleading claims, FDA says.
Medium -
DrugsGenesis Health International Inc. dba Genesis
FDA warns Genesis over misleading website claims for compounded semaglutide and tirzepatide.
Low -
DrugsAgebox Inc.
Agebox Inc. sells iKids-Growth children's supplements containing the undeclared, unapproved drug ibutamoren, making them unapproved and misbranded drugs.
High risk -
DrugsHandelnine Global, LLC dba Navafresh
Navafresh sells unapproved Ayurvedic drugs online, and its Rheumacare Capsules contain about 7,000 times the lead level of concern.
High risk -
DrugsMedical Mega
FDA: Medical Mega sells unapproved triclosan antiseptic soaps as nonprescription drugs.
Medium -
DrugsSinsin Pharmaceutical Co., Ltd.
FDA warned Sinsin Pharmaceutical that two Korean topical pain relievers sold in the US are unapproved and misbranded drugs.
High risk -
DrugsKorea Filler Experts
FDA warned Korea Filler Experts that its website sells unapproved and misbranded injectable botulinum toxin drugs, including Nabota 100UI, to U.S. consumers.
High risk -
DrugsIBSPOT.com Inc.
FDA says IBSPOT.com sold unapproved motion sickness patches containing diphenhydramine and diclofenac that the labels never listed.
High risk -
DrugsCosmenic
FDA warned Panama-based Cosmenic that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.
High risk -
DrugsDermacare dba Filler Outlet
South Korea's Dermacare, doing business as Filler Outlet, sells unapproved, misbranded injectable botulinum toxin to U.S. consumers through its website.
High risk -
DrugsMaypharm
Maypharm website sells unapproved, misbranded Botulax botulinum toxin to U.S. consumers, FDA says.
High risk -
DrugsEstaderma
FDA warned South Korea's Estaderma that its website sells unapproved, misbranded injectable botulinum toxin (Liztox) to U.S. consumers.
High risk -
DrugsKorean Aesthetic dba Korean Fillers
FDA warned Korean Fillers that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.
High risk -
DrugsCelestaPro
FDA told CelestaPro its website sells unapproved, misbranded injectable botulinum toxin drugs, including "Nabota 200 Unit", to U.S. consumers.
High risk -
DrugsAceCosm
AceCosm’s website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers, FDA says.
High risk -
DrugsDermax Co., Ltd
FDA warned China's Dermax Co., Ltd. over its website selling unapproved, misbranded injectable botulinum toxin to U.S. consumers.
High risk -
DrugsGlow Nest Beauty
FDA warned Glow Nest Beauty that its website sells unapproved, misbranded injectable botulinum toxin Rentox 200U.
High risk -
DrugsAesthetic Essentials Limited
Hong Kong company Aesthetic Essentials Limited sells not-FDA-approved, mislabeled injectable botulinum toxin drugs online to U.S. consumers.
High risk -
DrugsElle Pharm
FDA warned Elle Pharm that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.
High risk -
DrugsCOSMO KOREA
FDA told South Korea's COSMO KOREA that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.
High risk -
DrugsGlam Derma
FDA warns Glam Derma over website selling unapproved, misbranded injectable botulinum toxin products.
High risk -
DrugsMeamo
Meamo's website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers, FDA says.
High risk -
DrugsMJS Medicals
FDA warned South Korea's MJS Medicals for selling unapproved, misbranded botulinum toxin ("Innotox") to U.S. consumers online.
High risk -
DrugsDerma Solution
FDA warned Derma Solution for selling unapproved, misbranded injectable Botulax botulinum toxin drugs online to U.S. consumers.
High risk -
DrugsGlowface
Glowface's website sells unapproved, misbranded injectable Botulax botulinum toxin drugs to U.S. consumers, FDA says.
High risk